U.S. pharma giant copyright scrapped two experimental weight loss supplements previous calendar year—a at the time-day-to-day pill, lotiglipron, on account of elevated liver enzymes plus a two times-every day pill, danuglipron, on account of robust side effects—but CEO Albert Bourla has reported the company is decided to “Enjoy and get” ins